Flipped on its head.

Long term follow-up of two huge randomized trials indicates the use of post-menopausal / post-hysterectomy estrogen replacement significantly decreases the risk of breast cancer incidence and—get this—breast cancer mortality, something even primary prevention with tamoxifen can’t claim. We’ll leave it to the discussion section to elaborate on the current far-out theories as to why. | Chlebowski, JAMA 2020